Cited by 32Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchBioinformatics and Genomic Networks

Molecular differences in Alzheimer's disease between male and female patients determined by integrative network analysis

Open access
Sun, Lin‐Lin, Yang, Song‐Lin, Sun, Hui, Li, Wei‐Da, Duan, Shu‐Rong·2019·Journal of Cellular and Molecular Medicine

Abstract

Alzheimer's disease ( AD ) is a complex neurodegenerative disease and the most common cause of dementia among the elderly. There has been increasing recognition of sex differences in AD prevalence, clinical manifestation, disease course and prognosis. However, there have been few studies on the molecular mechanism underlying these differences. To address this issue, we carried out global gene expression and integrative network analyses based on expression profiles ( GSE 84422) across 17 cortical regions of 125 individuals with AD . There were few genes that were differentially expressed across the 17 regions between the two sexes, with only four (encoding glutamate metabotropic receptor 2, oestrogen‐related receptor beta, kinesin family member 26B, and aspartoacylase) that were differentially expressed in three regions. A pan‐cortical brain region co‐expression network analysis identified pathways and genes (eg, glycogen synthase kinase 3β) that were significantly associated with clinical characteristics of AD (such as neurofibrillary score) in males only. Similarity analyses between region‐specific networks indicated that male patients exhibited greater variability, especially in the superior parietal lobule, dorsolateral prefrontal cortex and occipital visual cortex. A network module analysis revealed an association between clinical traits and crosstalk of sex‐specific modules. An examination of temporal and spatial patterns of sex differences in AD showed that molecular networks were more conserved in females than in males in different cortical regions and at different AD stages. These findings provide insight into critical molecular pathways governing sex differences in AD pathology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcmm.13852

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. [1]Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016; 18: 437‐ 446. 28179815 PMC5286729
  2. [2]Wang M, Roussos P, McKenzie A, et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Med. 2016; 8: 104. 27799057 PMC5088659
  3. [3]Stamatelopoulos K, Sibbing D, Rallidis LS, et al. Amyloid‐beta (1‐40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015; 65: 904‐ 916. 25744007
  4. [4]Heun R. Does gender play a role in Alzheimer therapy? Expert Rev Neurother. 2002; 2: 589‐ 591. 19810972
  5. [6]Kim S, Kim MJ, Kim S, et al. Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer's disease: a CREDOS study. Compr Psychiatry. 2015; 62: 114‐ 122. 26343475
  6. [8]Corder EH, Ghebremedhin E, Taylor MG, et al. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004; 1019: 24‐ 28. 15246987
  7. [9]Fleisher A, Grundman M, Jack CR Jr, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005; 62: 953‐ 957. 15956166
  8. [10]Damoiseaux JS, Seeley WW, Zhou J, et al. Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012; 32: 8254‐ 8262. 22699906 PMC3394933
  9. [11]Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998; 50: 669‐ 677. 9521254
  10. [13]Siegel BV Jr, Shihabuddin L, Buchsbaum MS, Starr A, Haier RJ, Valladares Neto DC. Gender differences in cortical glucose metabolism in Alzheimer's disease and normal aging. J Neuropsy Clin Neurosci. 1996; 8: 211‐ 214. 9081560
  11. [16]Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: structure‐activity relationship. Mol Pharmacol. 1997; 51: 535‐ 541. 9106616
  12. [17]Davidson S, Golden JP, Copits BA, et al. Group II mGluRs suppress hyperexcitability in mouse and human nociceptors. Pain. 2016; 157: 2081‐ 2088. 27218869 PMC4988887
  13. [18]El Moustaine D, Granier S, Doumazane E, et al. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G‐protein coupling. Proc Natl Acad Sci USA. 2012; 109: 16342‐ 16347. 22988116 PMC3479612
  14. [19]Kim SH, Steele JW, Lee SW, et al. Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Abeta oligomer mouse. Mol Psychiatry. 2014; 19: 1235‐ 1242. 25113378 PMC4217144
  15. [20]Caraci F, Molinaro G, Battaglia G, et al. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta‐amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol. 2011; 79: 618‐ 626. 21159998
  16. [21]Sommer A, Sass JO. Expression of aspartoacylase (ASPA) and Canavan disease. Gene. 2012; 505: 206‐ 210. 22750302
  17. [22]Wijayasinghe YS, Pavlovsky AG, Viola RE. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective. Biochemistry. 2014; 53: 4970‐ 4978. 25003821
  18. [23]Zaroff S, Leone P, Markov V, Francis JS. Transcriptional regulation of N‐acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron‐glia communication during energetic crisis. Mol Cell Neurosci. 2015; 65: 143‐ 152. 25766789 PMC4393791
  19. [24]Yue X, Lu M, Lancaster T, et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA. 2005; 102: 19198‐ 19203. 16365303 PMC1323154
  20. [25]Li R, Singh M. Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol. 2014; 35: 385‐ 403. 24434111 PMC4087048
  21. [26]Andersson RH, Johnston A, Herman PA, et al. Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proc Natl Acad Sci USA. 2012; 109: 13118‐ 13123. 22822214 PMC3420189
  22. [27]Hu X, Hou H, Bastian C, et al. BACE1 regulates the proliferation and cellular functions of Schwann cells. Glia. 2017; 65: 712‐ 726. 28191691 PMC5357169
  23. [28]Makino C, Shibata H, Ninomiya H, Tashiro N, Fukumaki Y. Identification of single‐nucleotide polymorphisms in the human N‐methyl‐D‐aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr Genet. 2005; 15: 215‐ 221. 16094258
  24. [29]Yang SH, Perez E, Cutright J, et al. Testosterone increases neurotoxicity of glutamate in vitro and ischemia‐reperfusion injury in an animal model. J Appl Physiol. 2002; 92: 195‐ 201. 11744660
  25. [30]Llorens‐Martin M, Jurado J, Hernandez F, Avila J. GSK‐3beta, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7: 46. 24904272 PMC4033045
  26. [31]Baum L, Hansen L, Masliah E, Saitoh T. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Mol Chem Neuropathol. 1996; 29: 253‐ 261. 8971700
  27. [32]Konhilas JP, Maass AH, Luckey SW, Stauffer BL, Olson EN, Leinwand LA. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol. 2004; 287: H2768‐ H2776. 15319208 PMC2637113
  28. [33]Bertrand J, Despeaux M, Joly S, et al. Sex differences in the GSK3beta‐mediated survival of adherent leukemic progenitors. Oncogene. 2012; 31: 694‐ 705. 21725365
  29. [35]Jordan K, Wustenberg T, Heinze HJ, Peters M, Jancke L. Women and men exhibit different cortical activation patterns during mental rotation tasks. Neuropsychologia. 2002; 40: 2397‐ 2408. 12417468
  30. [36]Oti M, Brunner HG. The modular nature of genetic diseases. Clin Genet. 2007; 71: 1‐ 11. 17204041
  31. [37]Adamcsek B, Palla G, Farkas IJ, Derenyi I, Vicsek T. CFinder: locating cliques and overlapping modules in biological networks. Bioinformatics. 2006; 22: 1021‐ 1023. 16473872
  32. [38]Alfred T, Ben‐Shlomo Y, Cooper R, et al. Associations between APOE and low‐density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme. Age. 2014; 36: 9673. 25073452 PMC4150901
  33. [39]Rapoport SI. Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. Neurotox Res. 2003; 5: 385‐ 398. 14715441
  34. [40]Tsai CF, Hung CW, Lirng JF, Wang SJ, Fuh JL. Differences in brain metabolism associated with agitation and depression in Alzheimer's disease. East Asian Arch Psychiatry. 2013; 23: 86‐ 90. 24088401
  35. [41]Lee JH, Jiang Y, Han DH, Shin SK, Choi WH, Lee MJ. Targeting estrogen receptors for the treatment of Alzheimer's disease. Mol Neurobiol. 2014; 49: 39‐ 49. 23771838
  36. [42]Coffey CE, Lucke JF, Saxton JA, et al. Sex differences in brain aging: a quantitative magnetic resonance imaging study. Arch Neurol. 1998; 55: 169‐ 179. 9482358
  37. [43]Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009; 461: 218‐ 223. 19741703
  38. [44]Goodenough S, Schleusner D, Pietrzik C, Skutella T, Behl C. Glycogen synthase kinase 3beta links neuroprotection by 17beta‐estradiol to key Alzheimer processes. Neuroscience. 2005; 132: 581‐ 589. 15837120

Cited by

Sorted by citations

Authors
Sun, L., Yang, S., Sun, H., Li, W., & Duan, S.
Affiliations
  • Department of Neurology The First Affiliated Hospital of Harbin Medical University Harbin China
  • Department of Critical Care Medicine The First Affiliated Hospital of Harbin Medical University Harbin China
  • Harbin Medical University (CN)
  • First Affiliated Hospital of Harbin Medical University (CN)
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2018-11-05
Volume
23
Issue
1
Pages
47-58
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2900143604
Cited by
32
References
6
Citations by year
2026: 4 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 4
FWCI
2.06
Type
journal article
Language
en
Open access
Locations
  • Journal of Cellular and Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
Alzheimer's disease, sex differences, sex-specific gene expression, cortical regions, co-expression network, glycogen synthase kinase-3β, neurofibrillary tangles, aspartoacylase, disease stage, clinical traits
MeSH terms
Alzheimer Disease, Brain, Female, Humans, Male, Occipital Lobe, Sex Factors, Visual Cortex, Prefrontal Cortex, Gene Expression Profiling, Gene Regulatory Networks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review